The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Staph wars: the antibiotic pipeline strikes back
Abstract
Antibiotic chemotherapy is widely regarded as one of the most significant medical advancements in history. However, the continued misuse of antibiotics has contributed to the rapid rise of antimicrobial resistance (AMR) globally. Staphylococcus aureus , a major human pathogen, has become synonymous with multidrug resistance and is a leading antimicrobial-resistant pathogen causing significant morbidity and mortality worldwide. This review focuses on (1) the targets of current anti-staphylococcal antibiotics and the specific mechanisms that confirm resistance; (2) an in-depth analysis of recently licensed antibiotics approved for the treatment of S. aureus infections; and (3) an examination of the pre-clinical pipeline of anti-staphylococcal compounds. In addition, we examine the molecular mechanism of action of novel antimicrobials and derivatives of existing classes of antibiotics, collate data on the emergence of resistance to new compounds and provide an overview of key data from clinical trials evaluating anti-staphylococcal compounds. We present several successful cases in the development of alternative forms of existing antibiotics that have activity against multidrug-resistant S. aureus . Pre-clinical antimicrobials show promise, but more focus and funding are required to develop novel classes of compounds that can curtail the spread of and sustainably control antimicrobial-resistant S. aureus infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SCCmec mobility, driven by Ccr recombinases, enables rapid dissemination of resistance across MRSA lineages, underscoring the role of horizontal gene transfer in antibiotic resistance evolution [199,204].”
From Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms (2025) · cites this paper as [204]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Antimicrobial resistance: a global multifaceted phenomenon
Prestinaci, F., Pezzotti, P., & Pantosti, A. (2015) · Pathogens and Global Health · doi:10.1179/2047773215y.0000000030 · Cited by 3,296
Antimicrobial Resistance: Implications and Costs
Dadgostar, P. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s234610 · Cited by 2,024 · cited 1×
“Future predictions estimate that if left unchecked, AMR could lead to 10 million deaths per year and negatively impact global GDP to the tune of US $100 trillion [3].”
BackgroundStructural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase
Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., & Darst, S. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00286-0 · Cited by 1,556 · cited 1×
“Rather than preventing RNA polymerase from binding to the promoter and initiating transcription, RIF inhibits the formation of the first ribonucleotide phosphodiester bond, halting mRNA production [75].”
BackgroundLeclercq, R. (2002) · Clinical Infectious Diseases · doi:10.1086/324626 · Cited by 1,102
Tipper, D. J., & Strominger, J. L. (1965) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.54.4.1133 · Cited by 1,008 · cited 1×
“Thus β-lactams interrupt cell wall formation by covalently binding to PBPs and preventing the transpeptidase reaction from occurring, resulting in cell death [18].”
BackgroundErythromycin resistance by ribosome modification
Weisblum, B. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.3.577 · Cited by 1,008
Minocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
Antibiotic resistance in Staphylococcus aureus. Current status and future prospects
Foster, T. J. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux007 · Cited by 845
The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms
de Breij, A., Riool, M., Cordfunke, R. A., Malanovic, N., de Boer, L., Koning, R. I., Ravensbergen, E., Franken, M., van der Heijde, T., Boekema, B. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4044 · Cited by 555
Research works printed but not linked: 275
- 2019, Antibiotic resistance threats in the United States
- 10.1128/CMR.00134-14 · DOI · Paper page
- 10.3389/fimmu.2021.705360 · DOI · Paper page
- 10.1093/femsre/fuz030 · DOI · Paper page
- 10.1093/cid/ciad217 · doi:10.1093/cid/ciad217
- 10.1016/S0140-6736(21)02724-0 · DOI · Paper page
- 2019, Johns Hopkins ABX Guide
- 10.2217/17460913.2.3.323 · DOI · Paper page
- 10.2147/IDR.S173624 · DOI
- Moosavian, 2020, Characterization of Sccmec, SpA types and multidrug resistant of methicillin-resistant Staphylococcus aureus isolates in Ahvaz, Iran, Infect Drug Resist, 13, 1033, 10.2147/IDR.S244896 · DOI
- 10.1007/s10096-018-3300-0 · DOI
- 10.1093/jac/dkz401 · DOI
- 10.1038/nature17042 · DOI · Paper page
- 10.1016/S0140-6736(48)92166-7 · DOI · Paper page
- 10.1126/science.99.2579.452 · DOI · Paper page
- 10.5694/j.1326-5377.1955.tb35001.x · DOI
- 10.1172/JCI18535 · DOI · Paper page
- 10.1136/jcp.14.4.385 · DOI · Paper page
- 10.1128/AAC.44.6.1549-1555.2000 · DOI · Paper page
- 10.1128/jb.158.2.513-516.1984 · DOI · Paper page
- 10.1128/AAC.28.3.397 · DOI · Paper page
- 10.1128/AAC.6.6.722 · DOI
- 10.1042/bj1230773 · doi:10.1042/bj1230773
- 10.1101/cshperspect.a026989 · DOI · Paper page
- 10.1016/S0140-6736(97)07324-8 · DOI · Paper page
- 10.1126/science.1090956 · DOI · Paper page
- 10.1016/j.jgar.2014.04.006 · DOI
- 10.1128/AAC.00346-09 · DOI · Paper page
- 10.1016/0966-842X(96)10063-9 · DOI · Paper page
- 10.1016/j.jare.2019.10.005 · DOI · Paper page
- 10.2165/00003495-198224060-00002 · DOI
- 10.3109/07357909809032892 · doi:10.3109/07357909809032892
- 10.1592/phco.25.2.253.56956 · DOI
- 10.1006/jmbi.1997.0944 · DOI · Paper page
- 10.3389/fmicb.2018.01369 · DOI
- Hitchings, 2006, Inhibition of folate biosynthesis and function as a basis for chemotherapy, Adv Enzymol Relat Areas Mol Biol, 417
- 10.1006/jmbi.1996.0770 · DOI · Paper page
- 10.1128/AAC.49.9.3948-3951.2005 · DOI
- 10.1128/AAC.01128-08 · DOI
- 10.1111/j.1365-2958.1989.tb01805.x · DOI · Paper page
- 10.1093/jac/dkad063 · DOI
- 10.1016/j.bbamem.2006.02.009 · DOI · Paper page
- 10.1128/AAC.47.8.2538-2544.2003 · DOI · Paper page
- 10.1016/j.chembiol.2004.04.020 · DOI · Paper page
- 10.1038/s41467-020-15257-1 · DOI · Paper page
- 10.1371/journal.ppat.1000660 · DOI · Paper page
- 10.1128/mBio.01659-18 · DOI
- 10.1038/s41598-020-73108-x · DOI
- 10.1128/AAC.00970-15 · DOI
- 10.1128/AAC.00432-10 · DOI · Paper page
- 10.3389/fmicb.2022.948343 · DOI
- 10.1371/journal.pone.0067398 · DOI
- 10.1016/j.ijantimicag.2013.10.001 · DOI
- 10.1111/nyas.12948 · DOI · Paper page
- 10.1128/AAC.44.8.2160-2165.2000 · DOI
- 10.1038/s41598-020-80043-4 · doi:10.1038/s41598-020-80043-4
- 10.1128/AAC.42.5.1249 · DOI
- 10.1128/AAC.38.9.2014 · DOI · Paper page
- 10.1128/AAC.42.2.236 · doi:10.1128/aac.42.2.236
- 10.1128/AAC.33.9.1535 · DOI
- 10.1128/JB.187.7.2395-2405.2005 · DOI · Paper page
- 10.1128/AAC.50.3.1104-1107.2006 · DOI
- 10.1128/JB.184.5.1370-1377.2002 · DOI
- 10.1128/AAC.48.3.909-917.2004 · DOI
- 10.1128/AAC.01065-09 · DOI
- 10.1248/bpb.29.554 · DOI
- 10.1128/AAC.00580-10 · DOI · Paper page
- 10.1128/AAC.50.4.1276-1281.2006 · DOI
- 10.1093/jac/dkg212 · DOI
- 10.1128/AAC.50.1.298-309.2006 · DOI
- 10.1007/s10156-005-0417-8 · DOI
- 10.2147/IDR.S163634 · DOI
- 10.3389/fcimb.2019.00363 · DOI
- 10.1128/AAC.00398-11 · DOI
- 10.1093/labmed/lmw070 · doi:10.1093/labmed/lmw070
- 10.1073/pnas.83.16.6164 · DOI · Paper page
- 10.1093/jac/dkz544 · DOI
- 10.5812/jjm.29237 · DOI
- 10.2478/v10042-008-0034-3 · doi:10.2478/v10042-008-0034-3
- 10.1093/jac/43.2.253 · doi:10.1093/jac/43.2.253
- 10.2217/fmb.09.30 · DOI · Paper page
- 10.1093/jac/47.2.239 · doi:10.1093/jac/47.2.239
- 10.1128/aac.01696-22 · DOI
- 10.1016/S0924-8579(09)70005-6 · DOI · Paper page
- 10.1089/mdr.2017.0279 · DOI
- 10.3390/antibiotics10040398 · DOI · Paper page
- 10.1128/AAC.00131-06 · DOI · Paper page
- 10.1093/jac/dkv116 · DOI · Paper page
- 10.1186/s13756-020-00869-5 · doi:10.1186/s13756-020-00869-5
- 10.1016/s0022-2836(03)00662-4 · DOI · Paper page
- Westh, 1995, erm genes in erythromycin-resistant Staphylococcus aureus and coagulase-negative staphylococci, APMIS, 103, 225, 10.1111/j.1699-0463.1995.tb01099.x · doi:10.1111/j.1699-0463.1995.tb01099.x
- 10.3390/antibiotics10111406 · DOI · Paper page
- 10.1128/mBio.01975-15 · DOI · Paper page
- 10.1101/cshperspect.a025395 · DOI · Paper page
- 10.1128/AAC.02797-13 · doi:10.1128/aac.02797-13
- 10.1021/bi7015266 · doi:10.1021/bi7015266
- 10.1021/jm800038g · DOI · Paper page
- 10.1128/AAC.05702-11 · DOI · Paper page
- 10.3390/ph3071988 · DOI
- 10.1101/cshperspect.a027110 · DOI · Paper page
- 10.1128/AAC.01216-19 · DOI
- 10.1016/0006-291x(69)90934-6 · DOI · Paper page
- 10.1038/342142a0 · DOI · Paper page
- 10.1073/pnas.1320387110 · DOI
- 10.1101/cshperspect.a025437 · DOI
- 10.1086/499365 · DOI · Paper page
- 10.1038/srep19524 · DOI
- 10.1073/pnas.1117275109 · DOI
- 10.1038/nrmicro2278 · DOI · Paper page
- 10.1128/AAC.46.2.438-442.2002 · doi:10.1128/aac.46.2.438-442.2002
- 10.1128/AAC.38.5.1205 · DOI
- 10.1099/0022-1317-50-10-909 · doi:10.1099/0022-1317-50-10-909
- 10.1016/s0968-0896(03)00126-3 · DOI
- 10.1093/jac/dkf249 · DOI
- 10.1093/jac/dkq255 · DOI · Paper page
- 10.1093/jac/dkq255 · DOI · Paper page
- 10.1093/cid/cis559 · DOI
- 10.4137/CMRT.S1637 · DOI
- 10.1128/AAC.03622-14 · DOI
- 10.1128/AAC.01235-16 · DOI
- 10.1007/s40265-015-0384-z · doi:10.1007/s40265-015-0384-z
- 10.1128/AAC.00886-10 · doi:10.1128/aac.00886-10
- 10.1128/AAC.02294-20 · doi:10.1128/aac.02294-20
- 10.1016/j.ijantimicag.2011.03.002 · doi:10.1016/j.ijantimicag.2011.03.002
- 10.1093/jac/dkq375 · doi:10.1093/jac/dkq375
- 10.1128/AAC.02317-17 · DOI
- 10.1128/AAC.00078-09 · doi:10.1128/aac.00078-09
- 10.5772/intechopen.77863 · doi:10.5772/intechopen.77863
- 10.1016/j.jmii.2017.07.011 · doi:10.1016/j.jmii.2017.07.011
- 10.1089/mdr.2016.0021 · doi:10.1089/mdr.2016.0021
- 10.1089/mdr.2019.0048 · doi:10.1089/mdr.2019.0048
- 10.3390/antibiotics10121506 · DOI
- 10.2147/COPD.S90948 · DOI
- 10.21307/pjm-2019-007 · DOI
- 10.1128/AAC.47.10.3260-3269.2003 · DOI
- 10.1093/jac/dkh180 · DOI
- 10.1093/cid/ciy600 · DOI
- 10.1093/cid/ciy1079 · DOI
- 10.1128/AAC.02609-16 · doi:10.1128/aac.02609-16
- 10.1093/cid/ciy165 · DOI
- 10.1093/jac/dkx543 · DOI
- 10.1093/cid/ciz787 · DOI
- 10.2217/fmb-2017-0291 · doi:10.2217/fmb-2017-0291
- 10.1080/14787210.2019.1573671 · DOI
- 10.1128/AAC.01509-13 · DOI
- 10.2217/fmb-2017-0289 · doi:10.2217/fmb-2017-0289
- 10.2217/fmb.14.78 · doi:10.2217/fmb.14.78
- 10.1001/jamadermatol.2018.1103 · DOI
- 10.1128/AAC.00120-17 · doi:10.1128/aac.00120-17
- 10.1128/AAC.02169-17 · doi:10.1128/aac.02169-17
- Miki, 2020, Phase III double-blind comparative study of Lascufloxacin versus levofloxacin in patients with community-acquired pneumonia, Japanese J Chemother
- 10.1128/AAC.00120-17 · doi:10.1128/aac.00120-17
- 10.1358/dot.2020.56.6.3137167 · DOI
- 10.1093/jac/dkz493 · doi:10.1093/jac/dkz493
- 10.1093/jac/dkaa142 · doi:10.1093/jac/dkaa142
- 10.1128/AAC.01150-08 · DOI
- 10.1021/jm050035f · DOI
- 10.1128/AAC.48.9.3338-3342.2004 · DOI
- Bhatia, 2020, Efficacy and safety of a novel broad-spectrum anti-MRSA agent levonadifloxacin compared with linezolid for acute bacterial skin and skin structure infections: a Phase 3, openlabel, randomized study, J Assoc Physicians India, 68, 30
- 10.2147/DDDT.S229882 · DOI
- 10.1128/AAC.00641-06 · doi:10.1128/aac.00641-06
- 10.1007/s40265-015-0352-7 · DOI · Paper page
- 10.1016/j.bmc.2012.11.036 · DOI
- 10.1093/jac/dkv302 · DOI
- 10.37201/req/s01.06.2021 · doi:10.37201/req/s01.06.2021
- 10.1001/jama.2013.241 · DOI · Paper page
- 10.1016/S1473-3099(14)70737-6 · DOI · Paper page
- 10.1128/AAC.00663-10 · DOI
- 10.1093/jac/dkaa422 · DOI · Paper page
- 10.1128/AAC.00871-09 · DOI · Paper page
- 10.1124/dmd.114.061747 · DOI
- 10.4103/ipj.ipj_37_19 · DOI
- 10.1021/acs.chemrestox.0c00524 · DOI
- 10.1007/s40265-021-01576-0 · doi:10.1007/s40265-021-01576-0
- 10.3389/fmicb.2021.729900 · DOI
- 10.1021/jm201465w · DOI
- 10.1007/s10096-019-03590-3 · DOI
- 10.1002/phar.2366 · DOI
- 10.1001/jamasurg.2016.4237 · DOI · Paper page
- 10.1093/cid/ciy1029 · DOI · Paper page
- 10.1186/s12866-018-1349-7 · doi:10.1186/s12866-018-1349-7
- 10.3389/fmicb.2022.1043736 · DOI
- 10.1128/AAC.01242-13 · DOI · Paper page
- 10.1016/j.bmc.2016.07.029 · DOI
- 10.1128/AAC.01536-15 · DOI
- 10.1128/AAC.02488-19 · DOI
- 10.1093/ofid/ofx163.1413 · doi:10.1093/ofid/ofx163.1413
- 10.1007/s40265-018-1015-2 · doi:10.1007/s40265-018-1015-2
- 10.1016/S1473-3099(19)30275-0 · DOI
- 10.3389/fmicb.2019.02546 · DOI
- 10.1111/j.1749-6632.2011.06219.x · DOI
- 10.1101/cshperspect.a027110 · DOI · Paper page
- Novak, 2010, The pleuromutilin antibiotics: a new class for human use, Curr Opin Investig Drugs, 11, 182
- 10.1073/pnas.1517952112 · DOI
- 10.1128/AAC.02008-16 · DOI
- 10.1128/AAC.00627-16 · doi:10.1128/aac.00627-16
- 10.1093/jac/dks001 · doi:10.1093/jac/dks001
- 10.1128/AAC.05789-11 · doi:10.1128/aac.05789-11
- 10.1093/cid/ciz090 · DOI
- 10.1001/jama.2019.15468 · DOI
200 of 275 shown
Cited by
Staphylococcus aureus: A Review of the Pathogenesis and Virulence Mechanisms
Touaitia, R., Mairi, A., Ibrahim, N. A., Basher, N. S., Idres, T., & Touati, A. (2025) · Antibiotics · doi:10.3390/antibiotics14050470 · Cited by 273
Metadata
- Authors
- Douglas, E. J. A., & Laabei, M.
- Venue
- Microbiology
- Publisher
- Microbiology Society
- Published
- 2023-09-01
- Volume
- 169
- Issue
- 9
- ISSN
- 1350-0872
- 1465-2080
- Cited by
- 13
- References
- 13
- Language
- en
- Funders
- Academy of Medical Sciences (SBF006\1023)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Staph wars: the antibiotic pipeline strikes back. https://app.cochat.ai/papers/10.1099/mic.0.001387
- The paper
- Douglas, E. J. A., & Laabei, M. (2023). Staph wars: the antibiotic pipeline strikes back. Microbiology. https://doi.org/10.1099/mic.0.001387
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.